[HTML][HTML] ERK/MAPK signalling pathway and tumorigenesis

YJ Guo, WW Pan, SB Liu… - Experimental and …, 2020 - spandidos-publications.com
Mitogen‑activated protein kinase (MAPK) cascades are key signalling pathways that
regulate a wide variety of cellular processes, including proliferation, differentiation …

Marginal-zone lymphomas

D Rossi, F Bertoni, E Zucca - New England journal of medicine, 2022 - Mass Medical Soc
Marginal-Zone Lymphomas The third most common lymphoma, MZL is usually indolent and
often a consequence of chronic antigenic stimulation from a pathogen such as Helicobacter …

Genomic profiling for clinical decision making in lymphoid neoplasms

L De Leval, AA Alizadeh, PL Bergsagel… - Blood, The Journal …, 2022 - ashpublications.org
With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …

Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H

AKS Salama, S Li, ER Macrae, JI Park… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE BRAFV600 mutations are commonly found in melanoma and thyroid cancers
and to a lesser degree in other tumor types. Subprotocol H (EAY131-H) of the NCI-MATCH …

KRAS: From undruggable to a druggable Cancer Target

D Uprety, AA Adjei - Cancer treatment reviews, 2020 - Elsevier
RAS is the most frequently mutated oncogene in human cancers, with mutations in about
30% of all cancers. RAS exists in three different isoforms (K-RAS, H-RAS and N-RAS) with …

[HTML][HTML] Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for …

MM Li, M Datto, EJ Duncavage, S Kulkarni… - The Journal of molecular …, 2017 - Elsevier
Widespread clinical laboratory implementation of next-generation sequencing–based
cancer testing has highlighted the importance and potential benefits of standardizing the …

Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations

M Dankner, AAN Rose, S Rajkumar, PM Siegel… - Oncogene, 2018 - nature.com
Abstract The RAS–RAF–MEK–ERK signaling cascade is among the most frequently mutated
pathways in human cancer. Approximately 50% of melanoma patients possess a druggable …

Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders

C Kornauth, T Pemovska, GI Vladimer, G Bayer… - Cancer discovery, 2022 - AACR
Personalized medicine aims to match the right drug with the right patient by using specific
features of the individual patient's tumor. However, current strategies of personalized …

[HTML][HTML] Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

DM Hyman, I Puzanov, V Subbiah… - … England Journal of …, 2015 - Mass Medical Soc
Background BRAF V600 mutations occur in various nonmelanoma cancers. We undertook a
histology-independent phase 2 “basket” study of vemurafenib in BRAF V600 mutation …

Mutations driving CLL and their evolution in progression and relapse

DA Landau, E Tausch, AN Taylor-Weiner, C Stewart… - Nature, 2015 - nature.com
Which genetic alterations drive tumorigenesis and how they evolve over the course of
disease and therapy are central questions in cancer biology. Here we identify 44 recurrently …